ArticleJournal of lipid research2017
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Article in Journal of lipid research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Deletion of phosphatidylethanolamine methyltransferase promotes the spontaneous development of hepatic steatosis, inflammation, and fibrosis in young mice.Clinical science (London, England : 1979) · 2026Article
- PPARα regulates ER-lipid droplet protein Calsyntenin-3β to promote ketogenesis in hepatocytes.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Protocatechuic Acid Protects Mice Against Non-Alcoholic Fatty Liver Disease by Attenuating Oxidative Stress and Improving Lipid Profile.Reports of biochemistry & molecular biology · 2024Article
- Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation.Frontiers in pharmacology · 2024Article
- Phosphatidylethanolamine N-methyltransferase: from Functions to Diseases.Aging and disease · 2023Review
- Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design.Frontiers in pharmacology · 2023Article
- Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.Clinical science (London, England : 1979) · 2022Review
- Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models.PPAR research · 2022Review
- Targeting fatty acid metabolism for fibrotic disorders.Archives of pharmacal research · 2021Review
- Loss of Acot12 contributes to NAFLD independent of lipolysis of adipose tissue.Experimental & molecular medicine · 2021Article
- High-fat diet-induced upregulation of exosomal phosphatidylcholine contributes to insulin resistance.Nature communications · 2021Article
- Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.BioMed research international · 2021Article
- Impaired Hepatic Phosphatidylcholine Synthesis Leads to Cholestasis in Mice Challenged With a High-Fat Diet.Hepatology communications · 2019Article
- Effect of fenofibrate on uric acid level in patients with gout.Scientific reports · 2018Article
- Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.Molecular metabolism · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Mice lacking phosphatidylethanolamine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.